The record number of attendees, the expanded list of sponsors, and the recognition of customer awards marked this 20th anniversary event held at Mayflower Hotel in Washington D.C. as a milestone.
Philadelphia, October 22, 2026 / PRNewswire / -- A leading provider of revenue optimization technologies and consulting services to the pharmaceutical industry, IntegriChain, reviewed today the Access Insights Conference 2026 conference that took place from October 19 to 21 in Washington, D.C. Mayflower Hotel. For the second consecutive year, the conference sold out, highlighting the growing demand among pharmaceutical manufacturers to understand the increasingly complex commercialization and market access environments.
This year's conference also marks a milestone: IntegriChain celebrates its 20th anniversary in supporting biopharmaceutical manufacturers in achieving patient access and optimizing net revenue.
Sponsors
Access Insights In 2026, it has received strong support from a lineup of powerful commercial sponsors:
- Titanium Sponsor: GiftHealth
- Other sponsors: GoodRx, Asembia, Second Sight Solutions, PHIL, Medfuse, Lighthouse AI, Purple Lab, RxWare, Courier Health, and BioCareSD.
Agenda Highlights
The conference opened on Monday afternoon and was chaired by Josh Halpern, the Chief Executive Officer of IntegriChain. The session “AI at the Speed of Access” discussed how artificial intelligence is reshaping market access at an unprecedented speed and what this acceleration means for manufacturers; this also coincided with the 20th anniversary of IntegriChain. Subsequently, Bill Roth, the Senior Vice President of Consulting and Advisory Services, delivered a keynote speech titled “The Great Re - Pricing”, analyzing the increasingly fragmented payer market and the new realities it brings to pricing and access strategies. The afternoon concluded with several important roundtable discussions covering evolving healthcare policies, market dynamics, and commercialization strategies.
On Tuesday and Wednesday, the expert panels and hot topics centered around three major industry changes:
- Pricing, Policies, and Reimbursement – Responding to Changes in Medical Policies, Transitioning to Affordability Initiatives, GTN Modeling Innovations, and IRA /340B Operational Preparation
- Data and Technology – AI / ML Innovation, Next-Generation Data Architecture, Master Data Management, and Affordability Project Control
- Business and Strategy – Transforming Net Revenue Access, Pre-commercialization Decision-Making, Business Data Strategy, and Product Portfolio Optimization
Customer Award Winners
IntegriChain also recognized customers who have excelled in the commercialization of pharmaceuticals, demonstrating leadership and an innovative spirit:
- Commercialization Vision Award : Galderma
- Lighthouse Award : Incyte
- Zero to Launch Award : Cytokinetics
- ICyte Power User Award : Jim Peck, Merck
- Tina Patel Shining Light Award : Michelle Cerutti, Apellis
20th Anniversary
IntegriChain kicked off the 20th anniversary celebrations on Tuesday, October 20th, with a cocktail reception. Co-founders Kevin Leneinger and IntegriChain, along with the current CEO Josh Halpern, took to the stage to deliver inspiring speeches, celebrating the company's extraordinary journey over the past 20 years. IntegriChain is launching a multi-channel marketing campaign to celebrate its 20 years of helping biopharmaceutical manufacturers transform the complexities of commercialization into clear understanding. The campaign will highlight IntegriChain's role in helping the industry move from a spreadsheet-based past towards a more interconnected and real-time future through LinkedIn, YouTube, customer and employee stories, as well as thought leadership content. This anniversary not only serves as a review of the company's history but also marks the starting point for the next phase, aiming to help life science teams improve access, performance, and confidence throughout the entire commercialization lifecycle.
IntegriChain CEO Josh Halpern stated: "Twenty years have passed, and this community continues to prove that there is nothing more valuable than coming together to solve the most challenging issues in the access field. Selling out for two consecutive years indicates that we are precisely providing what the industry needs at this moment."
About IntegriChain
IntegriChain provides the only comprehensive data-driven commercialization platform in the biopharmaceutical industry, covering all aspects from strategy to operational execution, connecting the commercial, financial, and operational dimensions of drug access and profitability. Its ICyte ® platform integrates technology, data, consulting, and hosting services to unify key work processes, replacing manual procedures with integrated analysis and precise control.
Biopharmaceutical companies rely on IntegriChain to optimize patient access and net revenue performance, reduce losses, and enhance compliance, ensuring that every life-changing therapy can reach patients more quickly, more affordably, and in a more sustainable manner. The company receives support from Nordic Capital, a leading private equity investor focused on the industry with a broad portfolio in healthcare and technology.
IntegriChain is headquartered in Philadelphia, Pennsylvania, and has an office location in Pune, India.
Media Contact
Brandy Jensen, Senior Director/Co-Head of Marketing
IntegriChain
[ email protected ]
